Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Extending survival for people with hepatitis C using tobacco dependence treatment

The availability of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) has led WHO to advocate for the elimination of HCV. However, a 2017 Cochrane review1 suggests that DAA treatment might not improve morbidity and mortality in people living with HCV: trials have shown no benefit on these endpoints, despite a sustained virological response. Stefan Wiktor and John Scott (July 8, p 107)2 state that longer term observational data are needed to assess mortality in people receiving DAA treatment for HCV.